Press Releases and Statements

CHPA spoke today before a Food and Drug Administration Advisory Nonprescription Drugs Advisory Committee, during which the committee discussed data submitted by Galderma Laboratories, L.P. to support the supplemental new drug application for over-the-counter marketing of adapalene gel 0.1%.

CHPA released the following statement today in support of a Florida law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

CHPA elected officers and members to its Board of Directors at the association’s Annual Executive Conference, held March 14 through 16 at the Turnberry Isle Miami in Aventura, Florida.

CHPA commends the U.S. House of Representatives for swift passage of the Microbead-Free Waters Act of 2015 (H.R. 1321).

CHPA President and CEO Scott Melville released the following statement today regarding this afternoon’s House Energy and Commerce (E&C) Committee passage of the Microbead-Free Waters Act of 2015.

New members of the Consumer Healthcare Products Association (CHPA) Board of Directors were elected at the association’s board of directors meeting, held November 17 in Washington, D.C.

CHPA expresses its gratitude to New Jersey's governor, senator, and assembly members for shepherding the bill through the legislature. CHPA has long supported state efforts to curb teen OTC cough medicine abuse.

CHPA released the following statement in response to an article in Pediatrics, the official journal of the American Academy of Pediatrics, which reported a decline in emergency department visits for unsupervised medication exposures in young children.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).